 Asthma is a chronic inflammatory respiratory disease affecting an estimated 300 million people worldwide. 1  The annual direct treatment costs for asthma in Finland have reached over 200 million Euros and the indirect costs were estimated to be 470-550 million Euros. 2  The therapeutic efficacy of an inhalation therapy requires the drug(s) to reach the targeted areas of lower lung 3 and there is an increasing body of evidence to suggest that correct use of the inhalation device is critical for optimal drug delivery. 4
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 Asthma is a chronic inflammatory respiratory disease affecting an estimated 300 million people worldwide. 1  The annual direct treatment costs for asthma in Finland have reached over 200 million Euros and the indirect costs were estimated to be 470-550 million Euros. 2  The therapeutic efficacy of an inhalation therapy requires the drug(s) to reach the targeted areas of lower lung 3 and there is an increasing body of evidence to suggest that correct use of the inhalation device is critical for optimal drug delivery. 4  Studies have shown that inhaler use is often highly suboptimal. Research indicates that between 20-82% of patients (depending on the type of inhaler and method of assessment) do not master their dry powder inhalers. 
OBJECTIVE
 This was a single-site, single-visit, crossover study at the Åbo Akademi University, Turku, Finland.
 Healthy inhaler-naïve participants aged ≥18 years (N=120) were randomly assigned to one of the six assessment groups (Figure 1 ).
METHODS
 The majority of study participants (n=79; 66%) were aged 20-29 years old, 25% were male, and almost all participants (99%) were educated to a university level. 
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 To evaluate the proportion of participants achieving device mastery (defined as an absence of healthcare professional [HCP] observed errors), a three step approach was used:
1. intuitive use (with no instructions) 2. after reading the Finnish-or Swedish-language patient information leaflet (PIL) 3. after HCPs provided instructions for use.
 Trained HCPs monitored use and recorded errors based on the Device-Specific Handling Error Checklist (DSHEC), based on the approved PIL for each of the devices.
 Participants were observed using each of the three empty devices without active substance (Spiromax ® , Easyhaler ® , and Turbuhaler ® ; Figure 2 ) in a counter-balanced order.
 Descriptive and exploratory analyses were performed to assess the endpoint variables -the proportion of participants achieving device mastery at each of the three steps. The number, type, and characteristic of device handling errors were also assessed.
* One observation was added to the Easyhaler ® group in order to perform the statistical analysis. As such, these values might be an underestimate of the actual differences. ns: not significant.
 The device mastery level was high (>95%) with all three devices during Step 3 (after receiving instructions from the HCP).
 The number of participants observed making errors at each step varied between the three devices.  Since the types of device handling manoeuvres differ between Spiromax ® , Easyhaler ® and Turbuhaler ® , the percentages of handling errors were evaluated during preparation, inhalation and after inhalation in Steps 1-3 for each device and for each of the device-specific handling manoeuvres (Figure 3 ).
 The most common errors in
Step 1 were related to orientation for Spiromax ® (51.3%), shaking for Easyhaler ® (95.8%), and priming for Turbuhaler ® (55.8%).
 In general, age, educational level and gender were unrelated to device mastery (the majority of participants were 20-29 years of age, the educational level and age was similar for all participants [99% educated to a University level], and 75% were female).
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